High blood pressure, new drug. 2 injections a year is enough. I study

2024-07-28 12:08:47

The new therapy is administered with a simple subcutaneous injection.”

We had new drug from mRna to take care of high pressure, with only two injections per year. Revolution for those patients who cannot lower their blood pressure despite always following the prescribed treatments. Up to 50%, after one year, refuse antihypertensive treatment and thus the possibility of protecting the heart and brain from heart attack and stroke is also reduced. The new drug, Zilebesiran, currently in trials, seems promising, according to the Kardia-2 study presented at the American Academy of Cardiology’s ongoing in Atlanta. The website www.adnkronos.com writes it.

“The research results are very interesting: the new molecule interferes with messenger RNA by blocking the production of angiotensinogen in the liver, the protein at the top of the chain of organic processes that causes an increase in blood pressure values. Reducing the presence of this protein in the blood also reduces blood pressure”, explains Pasquale Perrone Filardi, President of the Italian Association of Cardiology and director of the school specializing in diseases of the cardiovascular system at the Federico II University of Naples.

“The new therapy is administered with ease subcutaneous injection What is done with insulin and its action lasts for a long time because it is enough to repeat it after 3 months or even 6 months – undergo specialist surgery – With this method of administration, patients who cannot follow the medical therapy of the doctor order. They will no longer have alibis and the treatment will be able to reduce excessive blood pressure values ​​without the need for other treatments”.

Kardia-2 study, double-blind and controlled placebopresented at the American Academy of Cardiology by Akshay S. Desai, associate professor at Harvard Medical School, evaluated the effectiveness and safety of Zilebesiran in 672 patients, in addition to daily medications.

“The patients registered, at the time of the first administration, had blood pressure levels, on average, of 143 mm Hg and showed an average reduction. systolic up to 18 mm Hg which, in most cases, remains stable for six months. These results open the way to the revolution of biological drugs also in the world of hypertension which needs them the most – concludes Perrone Filardi – for the insufficient commitment to take drugs throughout the human life”.